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Abstract
The malignant cell phenotype of Multiple Myeloma (MM) remains unclear with studies pro-
posing it to be either clonotypic B or proliferating plasma cells. Cancer/testis antigen MAGE
C1 is being extensively studied in MM and it has been suggested that it is involved in the
pathogenesis of the cancer. Therefore, we report on the use of MAGE C1 to determine the
malignant cell phenotype in MM using flow cytometry. Bone marrow aspirate (BM) and pe-
ripheral blood (PB) was collected from twelve MM patients at diagnosis, as well as three
MM disease-free controls. Mononuclear cells were isolated using density-gradient centrifu-
gation, and stabilized in 80% ethanol, before analysis via flow cytometry using relevant anti-
bodies against B cell development cell-surface markers and nuclear MAGE C1. MAGE C1
expression was observed consistently in the early stem cells (CD34+) and early pro-B to
pre-B cells (CD34+/−/CD19+), as well as the proliferating plasma cells in both the MM PB
and BM, while no expression was observed in the corresponding control samples. Mono-
clonality indicated a common origin of these cell types suggesting that the CD34+/MAGE
C1+ are the primary malignant cell phenotype that sustains the downstream B cell matura-
tion processes. Furthermore, this malignant cell phenotype was not restricted to the BM but
also found in the circulating PB cells.
Introduction
Multiple Myeloma (MM) is a haematological malignancy, characterised by the presence of
monoclonal immunoglobulin (Ig) in the peripheral blood (PB) and large numbers of neoplastic
plasma cells in the bone marrow (BM) [1–3]. Although, the disease mechanism responsible for
the malignant phenotype of MM remains unclear, studies have suggested that it may be a two-
compartment model comprising of both actively dividing and non-dividing cells which con-
tribute to the disease characteristics [4–7]. The precursor cell type responsible for disease initia-
tion remains the most contentious issue, with some studies supporting the theory that it is a
pre-B cell (CD138-) capable of self-renewal that feeds the growing population of non-dividing
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plasma cells, while others favour the idea that the disease initiating cell is solely a plasma cell
(138+) that is capable of regaining self-renewal characteristics [5,8–10].
While still controversial, the largest numbers of studies seem to favour the theory that clo-
notypic B (CD138-) cells are the precursor cells in MM [5,10–11]. However, the phenotypic
profile of malignant clonotypic B cells, linked to disease initiation, varies between studies indi-
cating that these cells resemble CD19+/CD27+/CD38- memory B cells or a slightly less differen-
tiated memory B-lymphocyte (CD20+/CD27+/CD34−/CD138−) as well as B cells with
haematopoietic stem cell-surface characteristics (CD34+/CD19+/−) [5,8,10,12]. Furthermore,
what stage in development clonotypic B cells become malignant is unclear, with studies sug-
gesting that clonotypic B cells originate in the BM (CD34+/CD19+/−) or from the lymphatic or-
gans (memory B cell) migrating to the BM giving rise to malignant plasma cells [5,8,10].
Identification and characterization of the malignant cell type in MM is important not only in
understanding the role of the clonotypic B cell in the pathogenesis and disease specific biology
of the cancer, but for effective treatment management of MM.
In the search for more answers, a group of genes that are actively being studied in MM are
cancer/testis antigens (CTAs) [6,13–15]. These genes show highly restricted expression, with
only testis tissue showing expression in all normal tissues thus far tested (including PB and
BM) and yet a very strong link to malignant cell types in a multitude of cancers [15–16].
MAGE C1 is the most commonly expressed CTA in MM, with 85% to 100% of symptomatic
MM patients expressing this antigen alone or with at least one other CTA [15,17]. Additionally,
expression of MAGE C1 is not limited to the stage of the cancer of MM [6,15,17]. Several
groups have suggested a direct role of this antigen in MM disease pathogenesis with Andrade
et al. [17] and Atanackovic et al. [18] suggesting that MAGE C1 expression is a primary event
in pathogenesis and may play a role in initiating abhorrent plasma cell proliferation in some
MM cases [6,14,19–20]. Although studies are limited at this stage, it is thought that MAGE C1
plays a role in cell-cycle progression and is important for MM cell survival [19–20]. As MAGE
C1 seems to play a role in the early development of MM, we used MAGE C1 antibodies in a
flow cytometric approach to link the abhorrent expression of this CTA to a specific stage in the
B cell maturation process in order to identify the primary malignant cell phenotype in MM.
Materials and Methods
Patient population and cell preparation
The study population consisted of twelve newly diagnosed, untreated symptomatic MM pa-
tients (as defined by the WHO classification) who were referred for BM biopsy at the Haema-
tology Division at Groote Schuur hospital, Western Cape, South Africa (Table 1). Three
healthy adult individuals (negative for any haematological diseases via immunocytochemistry
and microscopy) who were referred for BM biopsy, as donors for allogeneic transplants, were
also included in the study as controls (Table 1). HIV positive as well as dual-cancer pathology
patients were excluded from the study. No specific MM subtype was selected for analysis. Eth-
ics approval (HREC REF: 194/2012) was granted for this study from the Human Research Eth-
ics Committee University of Cape Town and all participants provided written informed
consent.
Approximately 5 ml BM aspirate and 10 ml PB were collected in EDTA tubes from each
participant. Samples from eight patients allowed corresponding BM and PB sample analysis,
while four additional patients were used for either PB or BM analysis only. Mononuclear cells
were isolated using Histopaque-1077 (Sigma-Aldrich, Inc, USA) density-gradient centrifuga-
tion and washed with red cell lysis buffer (0.144M NH4Cl and 0.01M NH4HCO3, pH 7.4) for
approximately 10 mins at 4°C. Thereafter, the mononuclear cells were fixed and permabilised
MAGEC1 and the Malignant Cell in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0120734 March 20, 2015 2 / 15
in 80% cold ethanol and stored at −20°C prior to flow cytometric analysis (BD Biosciences,
New Jersey).
Flow cytometry analysis
Cell-surface monoclonal anti-human antibodies included anti-CD19 phycoerythrin (PE),
anti-CD138 allophycocyanin (APC), anti-CD56 fluorescein isothiocyanate (FITC), anti-CD45
peridinin chlorophyll protein (PerCp), anti-CD34 (PE), anti-CD27 (PE), anti-CD19 (APC),
anti-CD13 (PE), anti-CD3 (PE), anti-CD33 (APC), anti-CD14 FITC, anti-Ig Lambda (Igλ)
(FITC) and anti-Ig Kappa (Igκ) (PE) from BD Biosciences (New Jersey), as well as anti-CD10
(APC), anti-CD20 (APC), anti-CD117 (APC) and anti-Ki-67 (FITC) from Biocom Biotech
(South Africa). Nuclear staining antibody for MAGE C1 (ABCAM, UK) was fluorescently la-
belled using the Mix-n-Stain CF 488A Antibody labelling kit (Sigma-Aldrich, Inc, USA) [22].
A series of antibody panels were used for this study: BM analysis: (1) CD45/CD138/CD56/
CD19; (2) CD45/CD138/Ki-67; (3) CD19/CD138/Igκ/Igλ; (4) CD138/CD45/Igκ/MAGE C1;
(5) CD45/CD19/CD10/MAGE C1; (6) CD45/CD27/CD20/MAGE C1; (7) CD45/CD34/
CD117/MAGE C1 and (8) CD45/CD19/CD34/MAGE C1; PB analysis: (1) CD45/CD19/
CD20/MAGE C1 and (2) CD45/CD34/CD19/MAGE C1.
For the analysis using each antibody panel, 2X106 ethanol fixed mononuclear cells were
washed twice in 40 ml ice-cold 1X PBS/1% FCS buffer (1500 rpm, at room temperature for
5 mins). Cells were finally re-suspended in 100 μl of cold 1X PBS/0.5% BSA buffer and 5 to
10 μl of each appropriate cell-surface antibody and 5 μg/ml of labelled MAGE C1 antibody were
added and incubated at 4°C for 30 mins in the dark. Labelled cells were washed with 1 ml cold
Table 1. Summary of MM patient characteristics at time of diagnosis.
MM patient/Donor number Sex, Age1 Stage of Disease at diagnosis (DS)2 CRAB3 Igκ/Igλ4
MM1 F, 56 IIa AB IgGκ
MM2 F, 66 IIa RAB IgGλ
MM3 M, 69 IIIa CRAB IgGλ
MM4 F, 71 IIb RAB IgGκ
MM5 F, 60 Ia CRAB IgGκ
MM6 M, 61 IIIa AB IgGκ
MM7 F, 43 IIIa CAB IgGλ
MM8 M, 80 IIIb CRAB IgAλ
MM9 F, 73 Ia AB IgGλ
MM10 F, 73 Ia B IgGκ light chain disease
MM11 M, 60 IIa RAB IgGκ
MM12 M, 33 IIa AB IgGκ
D1 F, 64 NA Neg Igκ and Igλ
D2 F, 53 NA Neg Igκ and Igλ
D3 M, 51 NA Neg Igκ and Igλ
MM: MM patient BM sample; D: Donor BM sample
1Sex was indicated as M (male) or F (female)
2Durie-Salmon staging system [1]
3Calcium >2.56 mmol/l; Renal: creatinine >90 μmol/l (F), >110 μmol/l (M); anemia: Hb <12 g/dl (F), <13 g/dl (M); bone lesions [45]
4Immunoglobulin G or A, Lambda (Igλ) or Kappa (Igκ) light chain staining of the plasma cells
doi:10.1371/journal.pone.0120734.t001
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1X PBS/0.5% BSA buffer at 1500 rpm for 5 mins, re-suspended in 1 ml cold 1X PBS/0.5% BSA
buffer and kept until flow cytometric analysis.
Quantitative fluorescence analysis was performed with four parameters on the BD Biosci-
ences FACsCalibur using CellQuest software (BD Biosciences) to collect and analyse data. Side
scatter (SS) and CD45 staining characteristics were used to first isolate specific leukocyte popu-
lation groups, which we had previously confirmed with appropriate markers, such as CD14,
CD13, CD33, CD19, CD34, CD3, CD10, CD138 [23–24]. These different cell population
groups were then selectively gated and the percentage of positive differential B cells, such as
stem/immature B lymphocytes, was determined via individual and dual antibody expression.
These positive cells for the various stages of B cell maturation were further selectively gated
and MAGE C1 expression was determined using histograms and the channel by channel sub-
traction method [25] with appropriate negative controls (gated areas<10% were regarded as
negative for MAGE C1 expression). Additionally donor BM and PB samples were used as con-
trols to exclude all non-specific binding of antibodies to monocytes and granulocytes to ensure
no false positive results. A minimum of 300 and 30,000 events per individual antibody and an-
tibody panel, respectively, were analysed with specific gating settings.
Determination of clonality with IgH specific PCR and capillary
electrophoresis
BM samples of patients with proliferating plasma cells were labelled as described above and
two populations isolated: CD45+/CD19+/CD34+/MAGE C1+ and CD45-/CD138+/MAGE C1+
using the FACS DIVA version 6.1.3 sorter. DNA was released from the sorted cells with heat
shock (99°C/5min) and used in a nested PCR to amplify the CDR3 region of the VDJ segment
in B cells using characterized primers [26–27]. The PCR conditions were as follows: 1.5 mM
MgCl2, 0.8 mM dNTPs, 25 pmol FR3A-FITC primer and JH primer, respectively, 3U Hot start
GoTaq (Promega, USA) and 1/10th PCR volume of heat-treated cell lysate. Cycle conditions in-
cluded 95°C for 5 min followed by 45 cycles of 94°C, 55°C and 72°C for 40 sec, respectively,
and a final extension of 72°C for 8 min. A second round of PCR was performed using the
amplicon of the first PCR as template to ensure optimal amplification. Hi-dye formamide (Ap-
plied Biosystems, Life Technologies) and ILS600 (Promega, USA) were added to undiluted
PCR products and separated via capillary electrophoresis on the ABI 3130xl (Applied Biosys-
tems) to determine clonality. Controls included extracted DNA from normal PB unfractio-
nated leukocytes and pro-B to pre-B cells from donor BM (polyclonal controls), EBV L1439A
(Epstein Barr virus transformed B-lymphocytes) in-house cell line (oligoclonal control),
Ramos (ATCC 1596) cell line (monoclonal control) and a no template PCR control.
Statistical analysis
Statistical analysis of the MAGE C1+ expression observed in the different cell populations in
the BM and PB of the MM samples was performed using the unpaired 2-tailed Student t-test
and the GraphPad Prism 6.05 software (www.graphpad.com/), with p-values<0.05 considered
statistically significant. The different cell populations with MAGE C1+ expression in the MM
BM and PB were compared between one another as well as to the corresponding donor BM
and PB samples, respectively.
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Results
Characterization of the BM of the MM patients
Classically, the MM disease is characterised using flow cytometric analysis of the monoclonal
plasma cell population in the BM [21,28–30]. In our research population, all the plasma cells in
the donor BM samples showed the expected CD45-/CD138+/CD19dim+/CD56-/Ki-67− pheno-
type, while the MM patients BM demonstrated mixed characteristics, including both κ and λ
clonality, abhorrent CD56, CD19 and CD117 expression and a variation in the presence of pro-
liferating plasma cells (>20% Ki-67 positivity) (Table 2) [28–31]. Overall, our MM patient
population represented a heterogeneous group of different genders, disease types, stages of the
cancer as well as varied cell surface characteristics that reflected the abnormal cell-surface anti-
body staining that is consistent with a MM diagnosis (Tables 1 and 2).
Determination and characterization of the cell phenotype expressing
MAGE C1
To determine which cellular populations were expressing MAGE C1 in both the BM and PB, a
series of antibody panels was used. The initial control donor investigations showed a high de-
gree of non-specific binding of the secondary antibody for MAGE C1 to the monocytic and re-
sidual granulocytic populations, despite various blocking strategies. Using antibodies including
CD14, CD13, and CD33 the monocytic and granulocytic populations were carefully determined
and specific gates were established to exclude all cells contributing to false positivity [23]. Thus
using specific gates as well as a combination of SS and CD45 expression to initially identify the
cell subgroups of interest, our analysis focused on the plasma cell, stem cell/immature B lym-
phocyte populations, as well as the mature B lymphocytes (pre-germinal centre) [24]. Based
on CD45 expression, bright MAGE C1 positive expression was associated with the stem/
immature B lymphocyte cell region in both the MM BM and PB samples of all patients, while a
second positive MAGE C1 subpopulation of proliferating plasma cells (dual Ki-67+/CD138+
Table 2. Summary of plasma cell characteristics in the MM BM study population.
MM patient/Donor number CD138 CD138/CD19 CD138/CD56 CD138/CD117 CD138/Ki-67
MM1 56* 3 99 90 Neg†
MM2 58 3 79 8 Neg
MM3 75 9 99 19 Neg
MM4 50 2 3 4 20
MM5 74 5 74 23 30
MM6 70 5 64 18 59
MM7 77 2 57 72 74
MM8 85 35 79 95 75
MM9 3 2 26 13 89
MM10 14 10 96 32 97
D1 5 6 4 5 Neg
D2 10 16 2 3 Neg
D3 19 11 7 12 Neg
* = Percentage of positive expression of single/dual plasma cell-surface and intracellular antibodies that were used to characterize the plasma cells in the
MM and donor samples.
† = <20% Ki-67 positivity.
MM: MM patient BM sample; D: Donor BM sample
doi:10.1371/journal.pone.0120734.t002
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phenotype) was observed in six patients in both the BM and corresponding PB sample, as well
as three additional patients with unmatched PB/BM samples. This population was identified
using a combination of antibody panels 2 and 4 to first selectively gate the proliferating plasma
cells in the CD138+ population (distinct subpopulation) and then investigate their MAGE C1
expression. Fig. 1 shows examples of the two distinct populations observed in the BM. No sig-
nificant MAGE C1 expression was observed in any of the donor or PB samples using this pro-
tocol, confirming a link to the MM diseased state.
To further investigate this CTA expression in the stem/immature lymphocyte B cell sub-
populations, MAGE C1 expression was determined along with known markers for the different
stages of B cell maturation. These included: CD34, CD10 and CD117 expression for early stem
cell/pro-B cells; CD34, CD10 and dim CD19 expression for pro-B to pre-B cells; bright CD19
expression for early to mid-immature B cells; CD20 expression for the late immature to naïve
B cells; CD27, dim CD138 and CD20 expression to identify memory B cells and CD138 expres-
sion for plasma cells [31,32–34]. Using the various antibody panels and negative controls deter-
mined in the validation of the study, the percentage of cells expressing MAGE C1 in both the
BM and PB of each MM patient was determined and is presented schematically in Figs. 2 and 3
respectively. While the cell population sizes varied between patients, the relative number of
these cells expressing MAGE C1 was fairly constant, and revealed a definite pattern with the
expression of this CTA closely linked to B cell maturation in all twelve patients. Importantly,
there was a very significant statistical difference in the expression of MAGE C1 between pa-
tients with MM and the expression in healthy donor controls. Fig. 4 shows the comparison in
MAGE C1 expression between the early stem cell population in both groups (p-value<0.001).
As shown in Fig. 2, a very early population of CD34+/MAGE C1+ cells (CD117-/CD19-/
CD10-) was observed in BM samples of all the MM patients, indicating that MAGE C1 was ex-
pressed at the very early stages of the B cell lineage. MAGE C1 expression continued in the
pro-B to pre-B cells (CD34+/CD117+ and CD19+/CD10+) and to the early to mid-immature B
cells (CD34-/CD19+/CD20dim+) (Fig. 2). However, analysis of MAGE C1 expression in the late
immature and memory cells (CD20, CD27, and Igκ and/or Igλ light chain expression) showed
that the protein was no longer being expressed in these cell types, indicating a specific develop-
mental link and a defined malignant cell population. This is clearly demonstrated in Fig. 4,
with the highly significant difference in the number of cells expressing MAGE C1 in the CD19+
vs CD27+ cell populations (p-value<0.0001) (Fig. 4).
As mentioned, a second MAGE C1 expressing population was observed in the seven pa-
tients that showed the presence of>20% proliferating plasma cells in the BM (Fig. 2). Impor-
tantly, this CTA expression was found to be only associated with the proliferating sub-
population of plasma cells. A second putative link of MAGE C1 expression to increased prolif-
eration was also observed with a notable increase in the number of proliferating early pro-B to
pre-B cells in MM patients BM (sub population demonstrating MAGE C1 positivity) compared
to the controls (ave 37% vs 7% (regarded as negative for proliferation)).
Although the cell types present in the PB were more limited, the pattern of MAGE C1 ex-
pression was similar to the BM, with circulating stem cells showing positivity (CD34+/CD19-),
as well as early to mid-immature B cells (CD34-/CD19+/CD20dim+) (Fig. 3). As the cells ma-
tured further and CD20 expression became more apparent, MAGE C1 was greatly reduced,
again reflecting the pattern observed in the BM. Fig. 4 shows the statistically highly significant
difference in the numbers of MAGE C1 positive cells in the CD19+ population vs the more ma-
ture CD20+ cells (p-value<0.0001). While circulating plasma cells were observed in the PB of
all the MM patients, MAGE C1 expression was only apparent in the proliferating plasma cell
population if present and corresponded with the expression in the matched BM samples (if ap-
plicable) (Fig. 3).
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Fig 1. Examples of flow cytometric analysis of the BM of a donor (A) and twoMM patients (B and C) to determine the different B cell lineage cell
populations expressing MAGE C1.Mononuclear cells from donor and MM patient BM were stained with different antibodies to determine the cell
phenotype and stage of B cell maturation where MAGE C1 was expressed.A and B: Density plots (SS and CD45) were used to selectively gate around
MAGEC1 and the Malignant Cell in Multiple Myeloma
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Determination of clonality of MAGE C1+ populations
To investigate the clonality of the proliferating plasma cells expressing MAGE C1 and the
MAGE C1+ pro-B to pre-B cells, the IgH VDJ region of these cells was analysed for size clonal-
ity. Specific primers for the CDR3 region were used on these sorted cell populations to amplify
the area of interest, followed by standard capillary electrophoresis analysis. Clonality controls
including donor unfractionated leukocytes from PB, pro-B to pre-B cells from donor BM
(MAGE C1−), an EBV-transformed B lymphocyte cell line and the clonal Ramos cell line, dem-
onstrated the ability of the assay to differentiate between polyclonal, oligoclonal and monoclo-
nal rearrangements in this region, respectively (examples shown in Fig. 5). PCR analysis of the
DNA from the CD19+/CD34+/MAGE C1+ (pro-B to pre-B cells) and CD138+/MAGE C1+
(proliferating plasma cells) sorted cells showed the presence of a single PCR fragment of 108
bp (Fig. 5), which indicated clonality in the two population groups and a strong indicator that
they originated from the same malignant clone.
Discussion
The precursor cell type responsible for disease initiation and ultimately the malignant pheno-
type in MM remains the most contentious issue. Unfortunately, the lack of a complete under-
standing of the disease pathogenesis has hampered efforts to effectively treat and cure this fatal
disease. In an effort to try to establish which cells carry a malignant signature, we chose to
study the expression of MAGE C1 in the B cell lineage of MM patients. MAGE C1 is a CTA
whose expression is associated with many malignant phenotypes [15–16] and thus is already
established as an abhorrent malignancy marker. It has also been shown to be expressed in most
MM cases and linked to the early development of the disease [17–18]. Using a flow cytometric
approach we were able to link expression of this malignant marker to two distinct B cell matu-
ration stages, including an early-stem cell-immature B lymphocyte continuum, as well as a de-
fined proliferating plasma cell population in the PB and BM. Importantly, MAGE C1
expression was not observed in any of the corresponding cell populations in samples from
healthy donors. Clonality studies indicated a putative common origin of these distinct cell
types. Despite the MM patients being heterogeneous in the number of plasma cells, cell-surface
characteristics and the number of proliferating plasma cells, the pattern of MAGE C1 expres-
sion was similar indicating a common disease mechanism. This novel use of CTA expression
in MM has provided a vital link between the various cells of the B cell lineage that are potential-
ly actively involved in MM pathogenesis.
Identification and characterization of MAGE C1 expression specifically to the early stages
of the B cell lineage supports the theory that the initial malignant cell phenotype is a primary B
cell [7,10–11,35]. Furthermore, high expression of this malignant marker was isolated to the
pre-B/early immature B cells, indicating that the initial phenotypic profile of the malignant cell
is not a post germinal centre memory cell as suggested by Matsui et al. [7–8]. Although clono-
typic B cells have been favoured to be the precursory cell in MM, many studies have also indi-
cated that plasma cells are not only responsible for the disease characteristics, but are also
specific cell populations including plasma cells (R1), stem/immature B lymphocytes (R2) and mature B lymphocytes (R3). Using various antibodies specific
to the cells of interest gated in R1, R2 and R3, cells with positive antibody expression were further selectively gated (R4) and MAGEC1 expression was
determined with histograms. A: Donor BM indicated that all selected cell populations were negative for MAGE C1 expression.B: MAGE C1 expression was
observed in the stem/immature B lymphocytes and not in the non-proliferating plasma or mature B lymphocytes of the MM patient.C: Density plots (SS and
CD45) were used to selectively gate the plasma cells (R1) and these cells were further confirmed with CD138 (R2). The proliferation index of the plasma cells
was determined with Ki-67 expression and this was correlated to MAGE C1 expression via histograms, respectively. MAGEC1 expression was only
observed in the proliferating plasma cells (Ki-67>20%). 1: Plasma cells, 2: Stem/immature B lymphocytes, 3: Lymphocytes, 4: Residual monocytes, 5:
Residual Granulocytes.
doi:10.1371/journal.pone.0120734.g001
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Fig 2. Schematic representation of the co-expression of B cell maturationmarkers and MAGEC1 in the relevant BM B-lymphocyte sub-
populations of MM patients and donors.MAGE C1 expression was observed in the very early stages of B cell maturation involving the CD34+, CD117+,
CD10+ and CD19+ cells (stem cells to early-mid immature B cells) in the BM, but was absent when light chain expression was expressed (naive and germinal
centre B cells). Positive MAGEC1 expression was also observed in the proliferating plasma cell population, but not in the preceding CD27+ memory cells
present in the BM. The percentage indicated is the number of cells in a specific cell population expressing MAGE C1 (as defined by a specific cell-surface
antigen). MM BM samples are ordered according to increasing MAGE C1+ expression on the plasma cells. MM 1 to 10 as well as D1 to 3 indicates the
different MM patient and donor profiles, respectively.
doi:10.1371/journal.pone.0120734.g002
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Fig 3. Schematic representation of the co-expression of B cell maturationmarkers and MAGEC1 in the relevant PB B-lymphocyte sub-
populations of MM patients and donors.MAGE C1 expression was observed in the very early stages of B cell maturation involving the CD34+ and CD19+
as well as the proliferating plasma cells in the PB. Additionally no MAGEC1 expression was observed in the late B cells (CD20+) in the PB. The percentage
indicated is the number of cells in a specific cell population expressing MAGE C1 (as defined by a specific cell-surface antigen). Kappa/Lambda light chain
expression as well as CD117, CD10 and CD27 antibodies were not investigated in the PB. MM 1 to 12 as well as D1 to 3 indicates the different MM patient
and donor profiles, respectively.
doi:10.1371/journal.pone.0120734.g003
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actively part of the malignant disease [8–9,36]. Our studies have shown that in MM patients
possessing proliferating plasma cells, which is already described as a more aggressive disease
[4,6], these plasma cells do indeed have truly malignant characteristics and will actively lead to
disease progression or relapse. However, the lack of MAGE C1 expression in the non-prolifer-
ating plasma cell bulk in other patients indicates that while these plasma cells cause the symp-
toms of the disease, they are not involved in the persistence of the disease. The monoclonality
of the MAGE C1+ pro-B to pre-B cell population compared to the oligoclonal donor pattern, as
well as the clonal similarity of the proliferating plasma cells in these patients, is similar to find-
ings in previous studies [3,35,37]. However, we have clearly shown a malignant clonal pheno-
type (MAGE C1 expression) between the two cell populations, which confirms a common cell
of origin for these malignant cells.
Fig 4. Statistical analysis of MAGE C1 expression in various B cell sub populations. An unpaired 2-tailed Student t-test was used to determine
statistical significance between the different cell populations expressing MAGEC1 as indicated, with p-values<0.05 considered to be statistically significant.
A: Comparison of the CD34+/MAGE C1+ cell population size found in the BM between the MM and donor groups.B: Comparison of the CD34+/MAGE C1+
cell population size found in the PB between the MM and donor groups.C: Comparison of the CD19+/MAGE C1+ and CD27+/MAGEC1+ cell population sizes
in the BM of the MM group.D: Comparison of the CD19+/MAGE C1+ and CD20+/MAGEC1+ cell population sizes in the PB of the MM group. *** = 0.0001
<p< 0.001. **** = p-value<0.0001.
doi:10.1371/journal.pone.0120734.g004
MAGEC1 and the Malignant Cell in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0120734 March 20, 2015 11 / 15
This common cell of origin has remained elusive in the past years. Similar to studies relating
to other cancers such as myeloid leukaemia [38–39], Matsui et al. [8] and Conway et al. [10]
suggested that the normal stem cell in MM differentiates to a rare cancer stem cell that is re-
sponsible for a major component of the disease. Likewise, our results indicate that the stem
cells observed in the BM had MAGE C1+ expression suggesting that the original stem cell has
differentiated to a cancer stem cell and can be the feeder and primary resistant malignant cell
phenotype of the downstream B lineage cells. Interestingly, the MAGE C1+/CD34+ cells (up to
25%) were found in circulation in the PB of the MM patients. This is similar to a study by
Szczepek et al. [5] where up to 30% of the abnormal stem cells were observed it the PB of MM
patients. Therefore, the MAGE C1+/CD34+ cells found in both the BM and PB of MM patients
indicates that the primary malignant cell is not confined to the BM and that migration between
these two sights allows for the spread of this cancer.
Controlling the extent of MM is one of the most important aspects of treatment to ensure
minimal spreading to other parts of the skeleton. Unfortunately, relapse is commonly observed
and studies have shown that clonotypic B lymphocytes can survive current MM chemotherapy
treatments [8,10,40]. The most effective treatment involves myeloablative therapy followed by
autologous PB blood progenitor cell (PBPC) transplantation [41–42]. However, this treatment
involves re-introducing the patient’s CD34+ cells back into the BM after chemotherapy, which
could potentially be problematic in almost ensuring a relapse, due to the lack of selection
against the malignant MAGE C1+/CD34+ that we identified in this study and their re-
Fig 5. Size clonality analysis of the VDJ region frommatched CD19+/CD34+/MAGE C1+ (pro-B to pre-B cells) and CD138+/MAGE C1+ (proliferating
plasma cells) cell populations. Using capillary electrophoresis and specific primers for the CDR3 region cell clonality in MM subpopulations was
investigated. As controls, the PB of a donor was analysed (A), as well as the CD19+/CD34+ isolated population from a donor BM sample (B), both showing
polyclonal populations as expected. Comparison of PCR amplicons from the pro-B to pre-B cells and proliferating plasma cells isolated from BM of a MM
patient with a large proliferating plasma cell population (MM9, 89%) indicated clonality of these two cell types (C and D).
doi:10.1371/journal.pone.0120734.g005
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introduction via transplantation. This is supported by the finding that in a randomized study
comparing disease-free and overall survival rates in patients receiving autologous PBPC trans-
plant of either CD34+ selected or unselected PBPCs no significant difference was found be-
tween the two groups 37 months post-transplant [42]. Optimal treatment would therefore not
only include reducing the plasma cell burden and M-protein levels, but specifically targeting
the malignant MAGE C1+/CD34+ cells before allogeneic transplantation to ensure that malig-
nant cells are not re-introduced into the patients BM.
Determining that MAGE C1 is expressed early in the B cell lineage (pre-B), as well as at the
end in the proliferating plasma cells, could indicate a definite role in pathogenesis of the dis-
ease. Studies have indicated that MAGE C1 can have a promoting effect on the survival of cells,
as well as an association with proliferation genes [6,14]. While we can suggest that MAGE C1
expression may be directly linked to the higher proliferation rate of the early B cells that we ob-
served in this study, further studies would need to be performed to confirm this. Interestingly,
MM patients with a high proliferation index have a much more aggressive disease, due to the
higher accumulation of plasma cells in the bone marrow [4,6,43]. The re-activation of MAGE
C1 expression in these plasma cells may indeed be linked to this proliferation.
The identification of the malignant feeder population in MM through the use of MAGE C1
in this study makes it an interesting target to pursue in targeted cell therapy approaches, such
as those employed using MAGE A3 in MM patients [44]. Furthermore, we suggest that MAGE
C1 can be used as a molecular marker to monitor patients for MRD using real-time quantita-
tive PCR or flow cytometry by regular monitoring of the various cell populations in the PB of
MM patients. This would give a more accurate reflection of disease load and allow more tar-
geted therapy on specific cell populations.
Acknowledgments
We would like to thank Professor Patrick Bouic (Synexa Group) for his insight into B cell mat-
uration and enthusiasm in the research.
Author Contributions
Conceived and designed the experiments: KS KW. Performed the experiments: KW. Analyzed
the data: KS KW. Contributed reagents/materials/analysis tools: KS. Wrote the paper: KS KW.
References
1. Durie GMB, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured mye-
loma cell mass with presenting clinical feature, response to treatment and survival. Cancer.1975; 36
(3):842–854. PMID: 1182674
2. Durie GMB. Staging and kinetics of Multiple Myeloma. Semin Oncol.1986; 13(3):300–309. PMID:
3532329
3. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski L. In multiple myeloma, clonotypic
B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and
monotypic Ig light chain. Blood.1995; 85(2):436–447. PMID: 7529064
4. Drewinko B, Alexanian R Boyer H, Barlogie B, Rubinour SI. The growth fraction of humanmyeloma
cells. Blood.1981; 57(2):333–338. PMID: 7448427
5. Szczepek J, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of
patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene
rearrangements. Blood.1997; 89(5):1824–1833. PMID: 9057669
6. Jungbluth A, Ely S, DiLiberto M, Williamson B, Frosina D, Chen YT, et al. The cancer-testis antigens
CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with
plasma-cell proliferation. Blood.2005; 106(1):167–174. PMID: 15761016
MAGEC1 and the Malignant Cell in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0120734 March 20, 2015 13 / 15
7. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma
progenitors, stem cell properties, and drug resistance. Cancer res.2008; 68(1):190–197. doi: 10.1158/
0008-5472.CAN-07-3096 PMID: 18172311
8. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y,et al. Characterization of clonogenic
multiple myeloma cells. Blood.2004; 103(6):2332–2336. PMID: 14630803
9. Yata K, Yaccoby S.The SCID-rab model: a novel in vivo system for primary humanmyeloma demon-
strating growth of CD138-expressing malignant cells. Leukemia.2004; 18(11):1891–1897. PMID:
15385929
10. Conway EJ, Wen J, Feng Y, Mo A, HuangWT, Keever-Taylor CA, et al. Phenotyping studies of clonoty-
pic B lymphocytes from patients with multiple myeloma by flow cytometry. Arch Path Lab Med.2009;
133(10):1594–1599. doi: 10.1043/1543-2165-133.10.1594 PMID: 19792049
11. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiat-
ing, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules.
Hematol Oncol Clin North Am.1992; 6(2):297–322. PMID: 1533857
12. Rasmussen T, Lodahl M, Hancke S, Johnson HE. In Multiple Myeloma Clonotypic CD38 − /CD19 +
/CD27 + Memory B Cells Recirculate Through Bone Marrow, Peripheral Blood and Lymph Nodes. Leuk
Lymphoma.2004; 45(7):1413–1417. PMID: 15359642
13. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F,et al. Genes encoding tumor-
specific antigens are expressed in humanmyeloma cells. Blood.1999; 94(4):1156–1164. PMID:
10438702
14. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, et al. Cancer/testis genes in
multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J
Immunol.2007; 178(5):3307–3315. PMID: 17312182
15. Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, et al. MAGE-C1/CT-7 expression in plas-
ma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci.2008; 99(4):720–
725. doi: 10.1111/j.1349-7006.2008.00738.x PMID: 18307538
16. Simpson AJ, Caballero OL, Jungbluth A, Chen Y-T, Old LJ (2005) Cancer/testis antigens, gametogene-
sis and cancer. Nat Rev cancer. 2008; 5(8):615–625.
17. Andrade VC, Vettore AL, Felix RS, Almeida MSS, de Carvalho F, Oliveira JS, et al. Prognostic impact
of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun.2008;
8:2–10. PMID: 18237105
18. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, et al. Longitudinal analysis and
prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin cancer res.2009; 15
(4):1343–1352. doi: 10.1158/1078-0432.CCR-08-0989 PMID: 19190130
19. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, et al. Cancer-testis antigens
MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica.2010;
95(5):785–793. doi: 10.3324/haematol.2009.014464 PMID: 20015885
20. de Carvalho F, Costa ET, Camargo A, Gregorio JC, Masotti C, Andrade VC, et al. Targeting MAGE-C1/
CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma
cell lines. PloS one.2011;16; 6(11):e27707. doi: 10.1371/journal.pone.002207 PMID: 22110734
21. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the Euro-
pean Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Haematologica.2008; 93(3):431–438. doi: 10.3324/haematol.11080 PMID: 18268286
22. Dhodarpkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of
cancer/testis (CT) antigens MAGE-A1, MAGE–A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gam-
mopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer
Immun.2003; 3:9–17. PMID: 12875607
23. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometry analysis of human bone mar-
row specimens. Clinical flow cytometry.1993; 677:265–279. PMID: 8494214
24. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal
B lymphocyte development. Blood.1987; 70(5):1316–1324. PMID: 3117132
25. Overton WR. Modified histogram subtraction technique for analysis of flow cytometry data. Cytome-
try.1988; 9:619–626. PMID: 3061754
26. Owen RG, Johnson RJ, Rawstron AC, Evans PA, Jack A, Smith GM, et al. Assessment of IgH PCR
strategies in multiple myeloma. J clinical pathol.1996; 49:672–675. PMID: 8881921
27. González M, González D, Lopez-Perez R, Garciá-Sanz R, Chillión MC, Balantzategui A, et al. Hetero-
duplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-
cell non-Hodgkin’s lymphoma. A comparison between different strategies. Haematologica.1999;
84:779–784. PMID: 10477449
MAGEC1 and the Malignant Cell in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0120734 March 20, 2015 14 / 15
28. Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentia-
tion, and expansions in relation to CD45 expression. Blood cells Mol Dis.2004; 32:293–301. PMID:
15003821
29. Bataille R, Gaëtan J, Robillard N, Barillė-Nion S, Harousseau J-L, Moreau P,et al. The phenotype of
normal, reactive and malignant plasma cell. Identification of “many and mulitple myelomas” and of new
targets for myeloma therapy. Haematologica.2006; 91(9):1234–1240. PMID: 16956823
30. Jeong TD, Park CJ, Shim H, Jang S, Chi HS, Yoon DH, et al. Simplified flow cytometric immunopheno-
typing panel for multiple myeloma, CD56/CD19/CD138 (CD38)/CD45, to differentiate neoplastic myelo-
ma cells from reactive plasma cells. Korean J Hematol.2012; 47(4):260–266. doi: 10.5045/kjh.2012.47.
4.260 PMID: 23320004
31. Ocqueteau M, Orfao A, García-Sanz R, Almeida J, Gonzalez M, San Miguel JF, et al. Expression of the
CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol.1996; 95(3): 489–493.
PMID: 8943889
32. Terstappen LW, Johnsen S, Segers-Nolten IM, Loken MR. Identification and characterization of plasma
cells in normal human bone marrow by high-resolution flow cytometry. Blood.1990; 76(9):1739–1747.
PMID: 2224123
33. Luque R, Brieva JA, Moreno A, Manzanal A, Escribano L, Villarrubia J, et al. Normal and clonal B line-
age cells can be distinguished by their differential expression of B cell antigens and adhesion molecules
in peripheral blood frommultiple myeloma (MM) patients—diagnostic and clinical implications. Clin Exp
Immunol.1998; 112:410–418. PMID: 9649209
34. Agematsui K, Hokibara S, Nagumo H, Komiyama A. CD27: A memory B-cell marker. Trends Immu-
nol.2000; 21(5):204–206. PMID: 10782048
35. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM, et al. A high frequency of circu-
lating B cells share clonotypic Ig heavy chain VDJ rearrangements with autologous bone marrow plas-
ma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase
chain reaction. Blood.1998; 92:2844–2855. PMID: 9763569
36. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu
host. Blood.1999; 94(10):3576–3582. PMID: 10552969
37. Billadeau D, Ahmann G, Greipp P, Ness B Van. The bone marrow of multiple myeloma patients con-
tains B cell populations at different stages of differentiation that are clonally related to the malignant
plasma cell. J Exp Med.1993; 178:1023–1031. PMID: 8350044
38. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med.1997; 3(7):730–737. PMID: 9212098
39. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour
initiating cells. Nature.2004; 432(7015):396–401. PMID: 15549107
40. Pilarski LM, Belch AR. Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of
multidrug-resistant disease in multiple myeloma. Blood.1994; 83(3):724–736. PMID: 7507731
41. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized
trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe
Francais de Myelome. N Engl J Med.1996; 335:91–97. PMID: 8649495
42. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-
blood stem cells using CD34 selection does not improve overall or progression free survival after high-
dose chemotherapy for multiple myeloma: Results of a multicentre randomized controlled trial. J Clin
Oncol.2001; 19(17): 3371–3779.
43. San Miguel JF, Garcia-Sanz R, González M, Moro MJ, Hernádez JM, Ortega F, et al. A new staging
system for Multiple myeloma based on the number of S-phase plasma cells. Blood.1995; 85(2):448–
455. PMID: 7811998
44. Rapoport AP, Aqui NA, Stadtmauer EA, Volgl DT, Xu YY, Kalos M, et al. Combination immunotherapy
after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive trans-
fer of vaccine-primed and costimulated autologous T cells. Clini Cancer Res. 2014; Feb 11. doi: 10.
1158/1078-0432.CCR-13-2817
45. Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, et al. Criteria for the classification
of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International My-
elomaWorking Group. Br J Haematol.2003; 121(5):749–757. PMID: 12780789
MAGEC1 and the Malignant Cell in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0120734 March 20, 2015 15 / 15
